Interim report Q2 2024
Business Highlights during the second quarter 2024
- Strengthened financial base with funding of DKK 27.8 million and potential of up to DKK 120 million in total.
- Clinical trial application accepted by the European Medicines Agency (EMA) for the investigation of uTRACE® in a phase 2 trial in prostate cancer.
- Second milestone payment received under the agreement with Curium Inc. using uTRACE® for the improved diagnosis in prostate cancer. USD 0.5 million was triggered following enrollment of the first patient in the phase 2 trial in prostate cancer.
- Plans proceeding to accelerate therapeutic strategy to secure development in parallel to ongoing uTRACE® activities.
Copenhagen, Denmark, 22 August 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Interim report Q2 2024. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
“During the second quarter of 2024, we have continued to build on our successes from the past year. We have enrolled the first patient in our phase 2 trial with uTRACE in prostate cancer and showed the rapid progress in our partnership with Curium, receiving the second milestone payment under this collaboration”, stated Curasight’s CEO Ulrich Krasilnikoff. “Additionally, we announced a capital raise aimed at further strengthening the company’s finances. The financing includes a directed share issue, a loan facility, and warrants which has initially provided DKK 27.8 million with the potential total fund raise of up to DKK 120 million, extending our cash runway well into the second half of 2025.”
Q2 (2024-04-01 – 2024-06-30)
- Gross loss amounted to kDKK -9,001 (kDKK –9,029)
- Operating loss amounted to kDKK -10,969 (kDKK -10,658)
- Loss before tax amounted to kDKK -12,112 (kDKK -10,658)
- Loss for the period amounted to kDKK -10,737 (kDKK -8,312)
- Total assets amounted to kDKK 28,847 (kDKK 46,331)
- Equity ratio amounted to 43.9% (95.8%)
- Earnings per share amounted to DKK -0.54 (DKK -0.41)
H1 (2024-01-01 – 2024-06-30)
- Gross loss amounted to kDKK -16,385 (kDKK –13,685)
- Operating loss amounted to kDKK -20,345 (kDKK -16,842)
- Loss before tax amounted to kDKK -21,479 (kDKK -16,844)
- Loss for the period amounted to kDKK -18,729 (kDKK -13,138)
- Total assets amounted to kDKK 28,847 (kDKK 46,331)
- Equity ratio amounted to 43.9% (95.8%)
- Earnings per share amounted to DKK -0.94 (DKK -0.66)
Numbers in parenthesis are the numbers from the same period in 2023.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.